Intraoperative electron radiation therapy

IntraOp Announces First Randomized Phase II Selection Trial of FLASH Versus Conventional Radiotherapy for Patients with Localized Carcinomas

Retrieved on: 
Friday, May 12, 2023

It marks the first time a randomized trial will compare FLASH radiotherapy* to conventional radiotherapy in treating nonmelanoma skin cancer (NMSC).

Key Points: 
  • It marks the first time a randomized trial will compare FLASH radiotherapy* to conventional radiotherapy in treating nonmelanoma skin cancer (NMSC).
  • It is the second clinical human trial to use the IntraOp® Mobetron® electron-based linear accelerator (LINAC).
  • “This feels like a breakthrough moment in our collective study of the role and effectiveness of FLASH radiotherapy as compared to standard of care radiotherapy.
  • *Ultra-High Dose Rate (UHDR) functionality for FLASH Radiotherapy is for investigational use only and is not cleared for sale by the US FDA.

IntraOp Medical Corporation Announces Their 10th Mobetron with FLASH-IQ Installation Worldwide

Retrieved on: 
Thursday, May 11, 2023

IntraOp Medical Corporation proudly announces that its IntraOp® Mobetron® with FLASH-IQ™ technology will soon be installed in its tenth institution worldwide, marking a significant milestone in the study of FLASH radiotherapy.

Key Points: 
  • IntraOp Medical Corporation proudly announces that its IntraOp® Mobetron® with FLASH-IQ™ technology will soon be installed in its tenth institution worldwide, marking a significant milestone in the study of FLASH radiotherapy.
  • IntraOp Mobetron with FLASH-IQ is a novel radiotherapy platform capable of delivering an Ultra-High Dose Rate (UHDR) electron beam.
  • Several additional sites are applying for IDEs in the US, along with Canada, Belgium and Germany applying for similar exemptions in their countries.
  • IntraOp supports these applications and looks forward to the continued growth and development in the study of FLASH radiotherapy.

Firsthand Technology Value Fund Discloses Revised Preliminary NAV of $3.75 Per Share as of March 31, 2023

Retrieved on: 
Wednesday, May 10, 2023

Firsthand Technology Value Fund, Inc. (NASDAQ: SVVC) (the “Fund”), a publicly traded venture capital fund that invests in technology and cleantech companies, disclosed today that its revised preliminary NAV, as of March 31, 2023, was $3.75.

Key Points: 
  • Firsthand Technology Value Fund, Inc. (NASDAQ: SVVC) (the “Fund”), a publicly traded venture capital fund that invests in technology and cleantech companies, disclosed today that its revised preliminary NAV, as of March 31, 2023, was $3.75.
  • As of March 31, 2023, the Fund’s investment in IntraOp consisted of preferred stock plus debt securities and represented approximately 55.3% of the Fund’s preliminary net assets.
  • The Fund’s preliminary net assets as of March 31, 2023, include cash and cash equivalents of approximately $0.12 per share.
  • As of March 31, 2023, the Fund’s top five holdings constituted 132.2% of the Fund’s preliminary net assets, and 96.7% of our preliminary total investments.

Firsthand Technology Value Fund Discloses Preliminary NAV of $4.10 Per Share as of March 31, 2023

Retrieved on: 
Friday, May 5, 2023

Firsthand Technology Value Fund, Inc. (NASDAQ: SVVC) (the “Fund”), a publicly traded venture capital fund that invests in technology and cleantech companies, disclosed today that its preliminary NAV, as of March 31, 2023, was $4.10.

Key Points: 
  • Firsthand Technology Value Fund, Inc. (NASDAQ: SVVC) (the “Fund”), a publicly traded venture capital fund that invests in technology and cleantech companies, disclosed today that its preliminary NAV, as of March 31, 2023, was $4.10.
  • As of March 31, 2023, the Fund’s investment in IntraOp consisted of preferred stock plus debt securities and represented approximately 50.7% of the Fund’s preliminary net assets.
  • The Fund’s preliminary net assets as of March 31, 2023, include cash and cash equivalents of approximately $0.12 per share.
  • As of March 31, 2023, the Fund’s top five holdings constituted 121.1% of the Fund’s preliminary net assets, and 96.7% of our preliminary total investments.

Firsthand Technology Value Fund Discloses Top Portfolio Holdings

Retrieved on: 
Thursday, April 6, 2023

Firsthand Technology Value Fund, Inc. (NASDAQ: SVVC) (the “Fund”), a publicly traded venture capital fund that invests in technology and cleantech companies, disclosed today that its top five holdings as of February 28, 2023, were IntraOp Medical, Wrightspeed, Hera Systems, Revasum, and EQX Capital.

Key Points: 
  • Firsthand Technology Value Fund, Inc. (NASDAQ: SVVC) (the “Fund”), a publicly traded venture capital fund that invests in technology and cleantech companies, disclosed today that its top five holdings as of February 28, 2023, were IntraOp Medical, Wrightspeed, Hera Systems, Revasum, and EQX Capital.
  • As of February 28, 2023, the Fund’s investment in IntraOp consisted of preferred stock plus debt securities and represented approximately 39.3% of the Fund’s estimated total investments.
  • *
    The Fund also announced that as of February 28, 2023, the estimated total investments* of the Fund were approximately $42.5 million, or $6.32 per share, including cash and cash equivalents of approximately $0.15 per share.
  • As of that date, the Fund’s top five holdings constituted 96.6% of the Fund’s estimated total investments.

Firsthand Technology Value Fund Discloses Top Portfolio Holdings

Retrieved on: 
Tuesday, March 7, 2023

Firsthand Technology Value Fund, Inc. (NASDAQ: SVVC) (the “Fund”), a publicly traded venture capital fund that invests in technology and cleantech companies, disclosed today that its top five holdings as of January 31, 2023, were IntraOp Medical, Wrightspeed, Hera Systems, Revasum, and EQX Capital.

Key Points: 
  • Firsthand Technology Value Fund, Inc. (NASDAQ: SVVC) (the “Fund”), a publicly traded venture capital fund that invests in technology and cleantech companies, disclosed today that its top five holdings as of January 31, 2023, were IntraOp Medical, Wrightspeed, Hera Systems, Revasum, and EQX Capital.
  • As of January 31, 2023, the Fund’s investment in IntraOp consisted of preferred stock plus debt securities and represented approximately 42.0% of the Fund’s estimated total investments.
  • *
    The Fund also announced that as of January 31, 2023, the estimated total investments* of the Fund were approximately $40.7 million, or $5.91 per share, including cash and cash equivalents of approximately $0.16 per share.
  • As of that date, the Fund’s top five holdings constituted 96.2% of the Fund’s estimated total investments.

Firsthand Technology Value Fund Discloses Preliminary NAV of $4.44 Per Share as of December 31, 2022

Retrieved on: 
Friday, February 3, 2023

Firsthand Technology Value Fund, Inc. (NASDAQ: SVVC) (the “Fund”), a publicly traded venture capital fund that invests in technology and cleantech companies, disclosed today that its preliminary NAV, as of December 31, 2022, was $4.44.

Key Points: 
  • Firsthand Technology Value Fund, Inc. (NASDAQ: SVVC) (the “Fund”), a publicly traded venture capital fund that invests in technology and cleantech companies, disclosed today that its preliminary NAV, as of December 31, 2022, was $4.44.
  • As of December 31, 2022, the Fund’s investment in IntraOp consisted of preferred stock plus debt securities and represented approximately 55.9% of the Fund’s preliminary net assets.
  • The Fund’s preliminary net assets as of December 31, 2022, include cash and cash equivalents of approximately $0.10 per share.
  • As of December 31, 2022, the Fund’s top five holdings constituted 125.0% of the Fund’s preliminary net assets, and 95.4% of our preliminary total investments.

IntraOp and Vanderbilt University Medical Center Announce First Patient Treated for Pancreatic Cancer Using Intra-Operative Radiation Therapy With Electrons

Retrieved on: 
Wednesday, January 18, 2023

IntraOp Medical Corporation announced today that doctors at Vanderbilt University Medical Center (VUMC) treated a pancreatic cancer patient using IntraOp® Mobetron® Intra-Operative Radiation Therapy (IORT).

Key Points: 
  • IntraOp Medical Corporation announced today that doctors at Vanderbilt University Medical Center (VUMC) treated a pancreatic cancer patient using IntraOp® Mobetron® Intra-Operative Radiation Therapy (IORT).
  • The procedure marks the first time VUMC — the largest comprehensive research, teaching and patient care health system in the Mid-South region — has utilized IORT with electrons in treating a patient with pancreatic cancer.
  • “We are encouraged by the results of the IORT with electrons in treating localized pancreatic cancer,” said Dr. Kamran Idrees.
  • “We serve our patients by implementing the latest innovations at Vanderbilt to improve outcomes.”
    Pancreatic cancer remains one of the deadliest forms of cancer.

Firsthand Technology Value Fund Discloses Top Portfolio Holdings

Retrieved on: 
Thursday, December 15, 2022

SAN JOSE, Calif., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Firsthand Technology Value Fund, Inc. (NASDAQ: SVVC) (the “Fund”), a publicly traded venture capital fund that invests in technology and cleantech companies, disclosed today that its top five holdings as of November 30, 2022, were IntraOp Medical, Wrightspeed, Hera Systems, Revasum, and EQX Capital.

Key Points: 
  • SAN JOSE, Calif., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Firsthand Technology Value Fund, Inc. (NASDAQ: SVVC) (the “Fund”), a publicly traded venture capital fund that invests in technology and cleantech companies, disclosed today that its top five holdings as of November 30, 2022, were IntraOp Medical, Wrightspeed, Hera Systems, Revasum, and EQX Capital.
  • Firsthand Technology Value Fund, Inc. is a publicly traded venture capital fund that invests in technology and cleantech companies.
  • More information about the Fund and its holdings can be found online at www.firsthandtvf.com .
  • Under normal circumstances, the Fund will invest at least 80% of its total assets for investment purposes in technology and cleantech companies.

Firsthand Technology Value Fund Discloses Top Portfolio Holdings

Retrieved on: 
Tuesday, November 22, 2022

SAN JOSE, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Firsthand Technology Value Fund, Inc. (NASDAQ: SVVC) (the Fund), a publicly traded venture capital fund that invests in technology and cleantech companies, disclosed today that its top five holdings as of October 31, 2022, were IntraOp Medical, Wrightspeed, Hera Systems, Revasum, and EQX Capital.

Key Points: 
  • SAN JOSE, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Firsthand Technology Value Fund, Inc. (NASDAQ: SVVC) (the Fund), a publicly traded venture capital fund that invests in technology and cleantech companies, disclosed today that its top five holdings as of October 31, 2022, were IntraOp Medical, Wrightspeed, Hera Systems, Revasum, and EQX Capital.
  • Firsthand Technology Value Fund, Inc. is a publicly traded venture capital fund that invests in technology and cleantech companies.
  • More information about the Fund and its holdings can be found online at www.firsthandtvf.com .
  • Under normal circumstances, the Fund will invest at least 80% of its total assets for investment purposes in technology and cleantech companies.